Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 1325 Next >>

Filter Applied: treatment of neurologic disorder (Click to remove)

Rocky Mountain Spotted Fever Encephalitis and "Starry Sky" Pattern on MRI, A Case Report
Neurologist 30:34-38, Mikhaiel,J.P.,et al, 2025

Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020

Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids:A Potentially Overlooked Diagnosis
Ann Neurol 95:407-409, Tsibonakis,A.,et al, 2024

Immunosuppressive Therapy Reversing Obstructive Hydrocephalus in CLIPPERS
Neurol 102:e209396, Yang,Y.,et al, 2024

Clinicopathologic Conference, Infective Endocarditis Due to Haemophilus Parainfluenza
NEJM 391:2148-2157, Case 38-2024, 2024

Clinical,Neuroimaging,and Genetic Markers in Cerebral Amyloid Angiopatny-Related Inflammation:A Systematic Review and Meta-Analusis
Stroke 54:178-188, Theodorou,A.,et al, 2023

Primary Diffuse Leptomeningeal Melanocytosis, A Diagnoatic Conundrum
Neurol 101:e576-3580, Selvarajan,J.M.P.,et al, 2023

MR Imaging Patterns and Prognosis in Powassan Virus Encephalitis
Neurologist doi.10.1097/NRI.0000000000000533, Finelli,P.F., 2023

Clinicopathologic Conference, Plasm-Cell Myeloma Post-Transplant Lymphoproliferative Disorder
NEJM 386:2508-2516, Case 20-2022, 2022

Clinicopathologic Conference, Granulomatosis with Polyangiitis
NEJM 387:1022-1032, Case 28-2022, 2022

Atypical Presentation of Primary Angiitis of Central Nervous System Responsive to Rituximab
Stroke 53:e490-e494, Kesav, P.,et al, 2022

Case 302:Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids
Radiology 303:726-730, Vattoth,S.,et al, 2022

Immunocompetent Patient with Multiple Cranial Nerve Palsies, Ataxia, and Cognitive Decline
Neurol 94:e225-e229, Nigam, M.,et al, 2020

Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020

A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019

Diagnostic Tools for Immune Causes of Encephalitis
Clin Microbiol Infect 25:431-436, Lascano, A.M.,et al, 2019

Basa Ganglia Calcifications (Fahrs Syndrome): Related Conditions and Clinical Features
Neurol Sci 40:2251-2263, Donzuso,G.,et al, 2019

Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
NEJM 379:1017-1027, Chitnis, T.,et al, 2018

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017

Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017

Glial Fibrillary Acidic Protein Immunoglobulin G as Biomarker of Autoimmune Astrocytopathy: Analysis of 102 Patients
Ann Neurol 81:298-309, Flanagan, E.P.,et al, 2017

Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Rapid Assessment and Treatment of Transient Ischemic Attacks and Minor Stroke in Canadian Emergency Departments
Stroke 46:2987-2990, Kamal, N.,et al, 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014

IgG4-Related Hypertrophic Pachymeningitis
JAMA Neurol 71:785-793, Lu, L.X.,et al, 2014

Amyloid-Beta Related Angiitis of the Central Nervous System: Case Report and Topic Review
Front Neurol 5:1-4, Nouh, A.,et al, 2014

Febrile Infection-Related Epilepsy Syndrome: A Study of 12 Patients
Seizure 22:553-559, Caraballo, R.H.,et al, 2013

Expanding the Clinical, Radiological and Neuropathological Phenotype of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)
JNNP 83:15-22, Simon, N.G.,et al, 2012

The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
NEJM 367:1087-1097,1149, Fox, R.J.,et al, 2012

Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012

Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011

N-methyl-D-aspartate Receptor Autoimmune Encephalitis Presenting With Opsoclonus-Myoclonus
Arch Neurol 68:1069-1072, Smith, J.H.,et al, 2011

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010

Spinal Cord Sarcoidosis: Clinical and Laboratory Profile and Outcome of 31 Patients in a Case-Control Study
Medicine 89:133-140, Cohen-Aubart,F.,et al, 2010

Impact od Adjuvant Chemotherapy for Gliomatosis Cerebri
BMC Cancer 10:424, Kong, D-S.,et al, 2010

Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009

Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009

Neurosarcoidosis: A Study of 30 New Cases
JNNP 80:297-304, Joseph,F.G. &Scolding,N.J., 2009

A 28-Year-Old Pregnant Woman with Encephalopathy
Neurol 73:e74-e79, Grinspan,Z.,et al, 2009



Showing articles 0 to 50 of 1325 Next >>